Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - glipizide, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; magnesium stearate - as an adjunct to diet and exercise for the control of hyperglycaemia and its associated symptomatology in patients with non-insulin dependent diabetes mellitus (niddm; type ii), formerly known as maturity onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory.,in initiating treatment for non insulin dependent diabetes, diet should be emphasised as the primary form of treatment. caloric restriction and weight loss are essential in the obese diabetic patient. proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycaemia. the importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified, and corrective measures taken where possible. if this treatment programme fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. use of melizide must be viewed by both the physician and patient as a treatment in addition to diet, and not

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow; iron oxide red - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - glipizide 5mg;   - tablet - 5 mg - active: glipizide 5mg   excipient: lactose monohydrate magnesium stearate pregelatinised maize starch starch water - melizide is an orally active hypoglycaemic sulphonylurea and is indicated as an adjunct to diet and exercise in the treatment of stable, mild to moderate, non-insulin dependent diabetes mellitus (type ii diabetes mellitus or niddm) without likelihood of ketosis, which cannot be adequately controlled by diet alone. treatment with melizide is indicated only if a satisfactory reduction in blood sugar has not been achieved by other measures, e.g. conscientious adherence to the recommended diet, weight reduction in overweight patients, and adequate exercise. in certain patients receiving insulin, the concurrent use of melizide allows a reduction in the daily dose of insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg; glibenclamide, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; quinoline yellow; iron oxide yellow; macrogol 4000; iron oxide red - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg; glibenclamide, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; iron oxide yellow; macrogol 4000; iron oxide red; iron oxide black - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 250 mg; glibenclamide, quantity: 1.25 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; iron oxide yellow; purified talc; macrogol 4000 - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: macrogol 400; magnesium stearate; lactose monohydrate; crospovidone; titanium dioxide; sucrose; polysorbate 80; povidone; colloidal anhydrous silica; hypromellose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; polysorbate 80; lactose monohydrate; macrogol 400; povidone; sucrose; hypromellose; magnesium stearate; titanium dioxide - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).